Monte Rosa Therapeutics (GLUE) Invested Capital (2023 - 2025)
Monte Rosa Therapeutics (GLUE) has 3 years of Invested Capital data on record, last reported at $245.8 million in Q3 2025.
- For Q3 2025, Invested Capital rose 19.65% year-over-year to $245.8 million; the TTM value through Sep 2025 reached $245.8 million, up 19.65%, while the annual FY2024 figure was $222.9 million, 24.37% up from the prior year.
- Invested Capital reached $245.8 million in Q3 2025 per GLUE's latest filing, down from $268.1 million in the prior quarter.
- Across five years, Invested Capital topped out at $275.2 million in Q1 2025 and bottomed at $152.5 million in Q1 2024.
- Average Invested Capital over 3 years is $219.6 million, with a median of $222.9 million recorded in 2024.
- Peak YoY movement for Invested Capital: plummeted 37.42% in 2024, then surged 80.41% in 2025.
- A 3-year view of Invested Capital shows it stood at $179.2 million in 2023, then grew by 24.37% to $222.9 million in 2024, then grew by 10.27% to $245.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Invested Capital were $245.8 million in Q3 2025, $268.1 million in Q2 2025, and $275.2 million in Q1 2025.